Simply Wall St.
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook?
📊
AI Sentiment
Positive
7/10
- Home
- IONS
as of 12-10-2025 2:15pm EST
$79.04
+$0.18
+0.23%
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Chart Type:
Time Range:
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 12.3B | IPO Year: | 1991 |
| Target Price: | $81.38 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $83.61 | Next Earning Date: | 10-29-2025 |
| Revenue: | $966,957,000 | Revenue Growth: | 20.41% |
| Revenue Growth (this year): | 29.66% | Revenue Growth (next year): | 1.88% |
AI-Powered IONS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 69.08%
69.08%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
WENDER JOSEPH H
Sell
Director
IONS Dec 1, 2025
Avg Cost/Share
$80.95
Shares
28,000
Total Value
$2,262,847.67
Owned After
36,035
HERMAN JOAN E
Sell
Director
IONS Nov 19, 2025
Avg Cost/Share
$72.13
Shares
44,000
Total Value
$3,173,830.00
Owned After
46,086
Birchler Brian
Sell
EVP, Corp and Development Ops
IONS Nov 6, 2025
Avg Cost/Share
$76.17
Shares
8,000
Total Value
$609,379.20
Owned After
48,826
SEC Form 4
Geary Richard S
Sell
EVP, Chief Development Officer
IONS Nov 6, 2025
Avg Cost/Share
$75.76
Shares
33,038
Total Value
$2,501,724.83
Owned After
59,657
Geary Richard S
Sell
EVP, Chief Development Officer
IONS Nov 5, 2025
Avg Cost/Share
$75.01
Shares
1,601
Total Value
$120,091.01
Owned After
59,657
Geary Richard S
Sell
EVP, Chief Development Officer
IONS Nov 3, 2025
Avg Cost/Share
$75.05
Shares
1,680
Total Value
$126,090.72
Owned After
59,657
LOSCALZO JOSEPH
Sell
Director
IONS Oct 31, 2025
Avg Cost/Share
$75.10
Shares
16,000
Total Value
$1,201,668.80
Owned After
36,330
SEC Form 4
Geary Richard S
Sell
EVP, Chief Development Officer
IONS Oct 31, 2025
Avg Cost/Share
$75.11
Shares
89,249
Total Value
$6,703,340.67
Owned After
59,657
WENDER JOSEPH H
Sell
Director
IONS Oct 31, 2025
Avg Cost/Share
$75.16
Shares
11,200
Total Value
$841,776.32
Owned After
36,035
SEC Form 4
WENDER JOSEPH H
Sell
Director
IONS Oct 30, 2025
Avg Cost/Share
$73.07
Shares
16,800
Total Value
$1,230,801.27
Owned After
36,035
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WENDER JOSEPH H | IONS | Director | Dec 1, 2025 | Sell | $80.95 | 28,000 | $2,262,847.67 | 36,035 | |
| HERMAN JOAN E | IONS | Director | Nov 19, 2025 | Sell | $72.13 | 44,000 | $3,173,830.00 | 46,086 | |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Nov 6, 2025 | Sell | $76.17 | 8,000 | $609,379.20 | 48,826 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 6, 2025 | Sell | $75.76 | 33,038 | $2,501,724.83 | 59,657 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 5, 2025 | Sell | $75.01 | 1,601 | $120,091.01 | 59,657 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Nov 3, 2025 | Sell | $75.05 | 1,680 | $126,090.72 | 59,657 | |
| LOSCALZO JOSEPH | IONS | Director | Oct 31, 2025 | Sell | $75.10 | 16,000 | $1,201,668.80 | 36,330 | |
| Geary Richard S | IONS | EVP, Chief Development Officer | Oct 31, 2025 | Sell | $75.11 | 89,249 | $6,703,340.67 | 59,657 | |
| WENDER JOSEPH H | IONS | Director | Oct 31, 2025 | Sell | $75.16 | 11,200 | $841,776.32 | 36,035 | |
| WENDER JOSEPH H | IONS | Director | Oct 30, 2025 | Sell | $73.07 | 16,800 | $1,230,801.27 | 36,035 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
Compare IONS vs Leading Stocks
See how IONS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.